Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Pharmacogenet Genomics. 2013 Feb;23(2):94–103. doi: 10.1097/FPC.0b013e32835cdabd

Figure 2.

Figure 2

Mediation of rs1051730 association with 6MO abstinence by nicotine dependence measures Fagerstrom Test for Nicotine Dependence (FTND) and cigarettes per day (CPD). a) Association of rs1051730 with 6MO abstinence without adjustment for nicotine dependence measures. The total path from rs1051730 to 6MO abstinence (not including the nicotine dependence measures FTND and CPD) is statistically significant at P<0.05. b) Mediation analyses of rs1051730 with 6MO abstinence with nicotine dependence measures. The direct path has a larger effect size and is more significant (P<0.01), than the total path in (a) above, due to the negative effects of FNTD and CPD on the total path. The path from rs1051730 through FTND to 6MO abstinence is statistically significant at P<0.05. The path from rs1051730 through CPD to 6MO abstinence is not statistically significant, though the association of rs1051730 with CPD is statistically significant at P<0.001.